PortfoliosLab logoPortfoliosLab logo

Documentation

Upgrade your plan
KRYS vs. KLAC
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

KRYS vs. KLAC

Last updated Apr 2, 2026

Compare and contrast key facts about Krystal Biotech, Inc. (KRYS) and KLA Corporation (KLAC).

Performance

KRYS vs. KLAC - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Krystal Biotech, Inc. (KRYS) and KLA Corporation (KLAC). The values are adjusted to include any dividend payments, if applicable.

Loading graphics...

KRYS vs. KLAC - Yearly Performance Comparison

2026 (YTD)202520242023202220212020201920182017
KRYS
Krystal Biotech, Inc.		5.02%57.37%26.28%56.60%13.25%16.58%8.34%166.51%97.53%-1.13%
KLAC
KLA Corporation		25.24%94.48%9.36%56.05%-11.20%68.05%47.94%103.99%-12.49%6.04%

Fundamentals

Market Cap

KRYS:

$7.75B

KLAC:

$200.93B

EPS

KRYS:

$6.86

KLAC:

$34.42

PE Ratio

KRYS:

37.72

KLAC:

44.16

PEG Ratio

KRYS:

0.09

KLAC:

1.65

PS Ratio

KRYS:

19.86

KLAC:

15.79

PB Ratio

KRYS:

6.36

KLAC:

36.76

Total Revenue (TTM)

KRYS:

$389.13M

KLAC:

$12.74B

Gross Profit (TTM)

KRYS:

$0.00

KLAC:

$7.89B

EBITDA (TTM)

KRYS:

$161.30M

KLAC:

$5.71B

Returns By Period

In the year-to-date period, KRYS achieves a 5.02% return, which is significantly lower than KLAC's 25.24% return.

KRYS

1D
0.23%
1M
0.04%
YTD
5.02%
6M
44.15%
1Y
48.30%
3Y*
47.88%
5Y*
27.54%
10Y*
—

KLAC

1D
3.22%
1M
-0.98%
YTD
25.24%
6M
35.03%
1Y
124.39%
3Y*
57.59%
5Y*
35.76%
10Y*
37.80%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Krystal Biotech, Inc.

KLA Corporation

Often compared with KRYS:
KRYS vs. COOPKRYS vs. VERXKRYS vs. FXAIXKRYS vs. LLYKRYS vs. CAMTKRYS vs. VOOKRYS vs. SCHG
Often compared with KLAC:
KLAC vs. LRCXKLAC vs. ASMLKLAC vs. ONTOKLAC vs. ASML.ASKLAC vs. SNPSKLAC vs. MPWRKLAC vs. INTT

Return for Risk

KRYS vs. KLAC — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.
KRYS
KRYS Risk / Return Rank: 7070
Overall Rank
KRYS Sharpe Ratio Rank: 7777
Sharpe Ratio Rank
KRYS Sortino Ratio Rank: 6969
Sortino Ratio Rank
KRYS Omega Ratio Rank: 7070
Omega Ratio Rank
KRYS Calmar Ratio Rank: 6868
Calmar Ratio Rank
KRYS Martin Ratio Rank: 6666
Martin Ratio Rank
KLAC
KLAC Risk / Return Rank: 9393
Overall Rank
KLAC Sharpe Ratio Rank: 9494
Sharpe Ratio Rank
KLAC Sortino Ratio Rank: 8989
Sortino Ratio Rank
KLAC Omega Ratio Rank: 9191
Omega Ratio Rank
KLAC Calmar Ratio Rank: 9595
Calmar Ratio Rank
KLAC Martin Ratio Rank: 9696
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

KRYS vs. KLAC - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Krystal Biotech, Inc. (KRYS) and KLA Corporation (KLAC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

KRYSKLACDifference

Sharpe ratio

Return per unit of total volatility

1.14

2.53

-1.39

Sortino ratio

Return per unit of downside risk

1.61

2.83

-1.22

Omega ratio

Gain probability vs. loss probability

1.22

1.41

-0.19

Calmar ratio

Return relative to maximum drawdown

1.37

5.59

-4.22

Martin ratio

Return relative to average drawdown

2.98

17.82

-14.83

Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

KRYS vs. KLAC - Sharpe Ratio Comparison

The current KRYS Sharpe Ratio is 1.14, which is lower than the KLAC Sharpe Ratio of 2.53. The chart below compares the historical Sharpe Ratios of KRYS and KLAC, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Loading graphics...

Sharpe Ratios by Period

KRYSKLACDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

1.14

2.53

-1.39

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.36

0.84

-0.48

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

—

0.93

—

Sharpe Ratio (All Time)

Calculated using the full available price history

0.61

0.43

+0.18

Correlation

The correlation between KRYS and KLAC is 0.27, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

KRYS vs. KLAC - Dividend Comparison

KRYS has not paid dividends to shareholders, while KLAC's dividend yield for the trailing twelve months is around 0.50%.

TTM20252024202320222021202020192018201720162015
KRYS
Krystal Biotech, Inc.		0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
KLAC
KLA Corporation		0.50%0.61%0.96%0.92%1.25%0.91%1.35%1.74%3.17%2.15%2.67%2.94%

Drawdowns

KRYS vs. KLAC - Drawdown Comparison

The maximum KRYS drawdown since its inception was -53.42%, smaller than the maximum KLAC drawdown of -83.74%. Use the drawdown chart below to compare losses from any high point for KRYS and KLAC.

Loading graphics...

Drawdown Indicators

KRYSKLACDifference

Max Drawdown

Largest peak-to-trough decline

-53.42%

-83.74%

+30.32%

Max Drawdown (1Y)

Largest decline over 1 year

-31.85%

-22.41%

-9.44%

Max Drawdown (5Y)

Largest decline over 5 years

-51.34%

-40.28%

-11.06%

Max Drawdown (10Y)

Largest decline over 10 years

—

-40.28%

—

Current Drawdown

Current decline from peak

-11.31%

-9.67%

-1.64%

Average Drawdown

Average peak-to-trough decline

-16.43%

-29.46%

+13.03%

Ulcer Index

Depth and duration of drawdowns from previous peaks

14.61%

7.03%

+7.58%

Volatility

KRYS vs. KLAC - Volatility Comparison

The current volatility for Krystal Biotech, Inc. (KRYS) is 9.78%, while KLA Corporation (KLAC) has a volatility of 16.05%. This indicates that KRYS experiences smaller price fluctuations and is considered to be less risky than KLAC based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Loading graphics...

Volatility by Period

KRYSKLACDifference

Volatility (1M)

Calculated over the trailing 1-month period

9.78%

16.05%

-6.27%

Volatility (6M)

Calculated over the trailing 6-month period

25.71%

37.13%

-11.42%

Volatility (1Y)

Calculated over the trailing 1-year period

42.66%

49.40%

-6.74%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

76.66%

42.59%

+34.07%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

74.80%

40.94%

+33.86%

Financials

KRYS vs. KLAC - Financials Comparison

This section allows you to compare key financial metrics between Krystal Biotech, Inc. and KLA Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.

Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities

0.00500.00M1.00B1.50B2.00B2.50B3.00B3.50BAprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober
107.11M
3.30B
(KRYS) Total Revenue
(KLAC) Total Revenue
Values in USD except per share items